Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Bionano Genomics, Inc.

Get SEC filing alerts via email and in your feed for Bionano Genomics, Inc.

BNGO

Bionano Genomics, Inc.

About Bionano Genomics, Inc.

Bionano Genomics, Inc. develops and markets optical genome mapping (OGM) systems, software, and nucleic acid purification solutions for comprehensive structural variation (SV) analysis in genomics. Its core products include the Saphyr® and Stratys™ OGM systems, VIA™ software for integrated genomic data interpretation, and the Ionic® Purification system. Serving researchers, clinicians, and biopharmaceutical companies, Bionano’s platform offers a scalable, cost-effective alternative to traditional cytogenetics and sequencing for genetic disease, cancer, and cell therapy applications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Bionano Genomics, Inc.

1
1
Bionano Genomics, Inc. Bionano Genomics Reports $6.7M Revenue in Q1 2026, Faces Liquidity Challenges

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Bionano Genomics, Inc. Bionano Genomics Reports $26.4 Million Net Loss for 2025, Revenue Declines to $28.5 Million

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Bionano Genomics, Inc. Bionano Genomics Reports 21% Revenue Growth but Faces $8.5 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Bionano Genomics, Inc. Bionano Genomics Reports 13% Revenue Decline in Q2 2025, Operating Loss Improves

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Bionano Genomics, Inc. Bionano Genomics Reports 26% Revenue Decline to $6.46 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Bionano Genomics, Inc. Bionano Genomics Reports $30.7 Million Revenue and $112 Million Net Loss for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Bionano Genomics, Inc. Bionano Genomics Reports Significant Financial Decline, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments